JP2021518361A5 - - Google Patents

Info

Publication number
JP2021518361A5
JP2021518361A5 JP2020549641A JP2020549641A JP2021518361A5 JP 2021518361 A5 JP2021518361 A5 JP 2021518361A5 JP 2020549641 A JP2020549641 A JP 2020549641A JP 2020549641 A JP2020549641 A JP 2020549641A JP 2021518361 A5 JP2021518361 A5 JP 2021518361A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
peptide
oligonucleotide conjugate
acceptable salt
chimeric peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020549641A
Other languages
English (en)
Japanese (ja)
Other versions
JP7596148B2 (ja
JP2021518361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022475 external-priority patent/WO2019178479A1/en
Publication of JP2021518361A publication Critical patent/JP2021518361A/ja
Publication of JP2021518361A5 publication Critical patent/JP2021518361A5/ja
Priority to JP2024159928A priority Critical patent/JP2024163336A/ja
Application granted granted Critical
Publication of JP7596148B2 publication Critical patent/JP7596148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020549641A 2018-03-16 2019-03-15 アンチセンス送達用キメラペプチド Active JP7596148B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024159928A JP2024163336A (ja) 2018-03-16 2024-09-17 アンチセンス送達用キメラペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644202P 2018-03-16 2018-03-16
US62/644,202 2018-03-16
PCT/US2019/022475 WO2019178479A1 (en) 2018-03-16 2019-03-15 Chimeric peptides for antisense delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024159928A Division JP2024163336A (ja) 2018-03-16 2024-09-17 アンチセンス送達用キメラペプチド

Publications (3)

Publication Number Publication Date
JP2021518361A JP2021518361A (ja) 2021-08-02
JP2021518361A5 true JP2021518361A5 (enExample) 2023-08-28
JP7596148B2 JP7596148B2 (ja) 2024-12-09

Family

ID=67908050

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020549641A Active JP7596148B2 (ja) 2018-03-16 2019-03-15 アンチセンス送達用キメラペプチド
JP2024159928A Pending JP2024163336A (ja) 2018-03-16 2024-09-17 アンチセンス送達用キメラペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024159928A Pending JP2024163336A (ja) 2018-03-16 2024-09-17 アンチセンス送達用キメラペプチド

Country Status (6)

Country Link
US (2) US12370261B2 (enExample)
EP (1) EP3765030A4 (enExample)
JP (2) JP7596148B2 (enExample)
MA (1) MA52148A (enExample)
TW (1) TW202002990A (enExample)
WO (1) WO2019178479A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079386A1 (en) * 2017-10-17 2019-04-25 Sarepta Therapeutics, Inc. CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION
WO2021150867A1 (en) * 2020-01-24 2021-07-29 Sarepta Therapeutics, Inc. Designing antisense oligonucleotide delivery peptides by interpretable machine learning
WO2022171972A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
WO2026080471A2 (en) 2024-10-07 2026-04-16 Flagship Pioneering Innovations Vi, Llc Compositions of trem conjugates and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
WO2007009094A2 (en) 2005-07-13 2007-01-18 Avi Biopharma, Inc. Antisense antibacterial method and compound
PL2735568T3 (pl) 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009147368A1 (en) * 2008-06-04 2009-12-10 Medical Research Council Peptides
CA3092114A1 (en) 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EP2755690B1 (en) 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
PE20181541A1 (es) * 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
JP6496549B2 (ja) 2011-11-30 2019-04-03 サレプタ セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
EP2900821B1 (en) * 2012-09-25 2020-04-01 Genzyme Corporation Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
WO2014124952A1 (en) 2013-02-12 2014-08-21 Syddansk Universitet "clickable" alkyne-lna oligonucleotides
US20140315977A1 (en) 2013-03-14 2014-10-23 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US20140329762A1 (en) * 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US11371994B2 (en) 2013-09-13 2022-06-28 California Institute Of Technology Phosphorylated Akt-specific capture agents, compositions, and methods of using and making
BR112016013516A8 (pt) * 2013-12-12 2020-05-19 Life Technologies Corp complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula
GB201421379D0 (en) 2014-12-02 2015-01-14 Isis Innovation Ltd And Medical Res Council Molecule
WO2017066789A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2019079386A1 (en) 2017-10-17 2019-04-25 Sarepta Therapeutics, Inc. CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION
JP7564087B2 (ja) * 2018-07-30 2024-10-08 サレプタ セラピューティクス， インコーポレイテッド アンチセンス送達のための三量体ペプチド

Similar Documents

Publication Publication Date Title
JP2021518361A5 (enExample)
JP2021532784A5 (enExample)
JP2758988B2 (ja) ペプチド核酸
US7910726B2 (en) Amidite for synthesizing modified nucleic acid and method for synthesizing modified nucleic acid
JP3210672B2 (ja) 新規ペプチド核酸
US6441130B1 (en) Linked peptide nucleic acids
US8859490B2 (en) Peptide nucleic acid monomers and oligomers
JP2024506099A5 (enExample)
CA2131755A1 (en) Nucleic acid-binding oligomers possessing n-branching for therapy and diagnostics
JP2020537654A5 (enExample)
De Cola et al. Carboxyalkyl peptoid PNAs: synthesis and hybridization properties
JP5195757B2 (ja) 核酸合成用ダイマーアミダイド及び核酸合成方法
US8288516B2 (en) Functional molecule, functional molecule synthesizing amidite and target substance analysis method
DE4331011A1 (de) Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
AU2020324396B2 (en) Compositions of trofinetide
JP2025513521A (ja) 治療薬を送達するための環状ペプチド
CN114901673B (zh) 溶液相肽核酸寡聚体的制备方法
AU2022291626A1 (en) Improved process for preparing imetelstat
US10174075B2 (en) Use of a tetraphenylborate (TPB) salt for the separation of biomolecules
Hudson et al. The detrimental effect of orotic acid substitution in the peptide nucleic acid strand on the stability of PNA2: NA triple helices
JP2007511573A (ja) 癌の治療のための置換キノリン
US20210163541A1 (en) Method for Preparing PNA Oligomer
US20030105286A1 (en) Linked peptide nucleic acids
EP2291391B1 (en) Use of a tpb salt for the separation of biomolecules
JP2009507765A (ja) ユニバーサル塩基を含むｐｎａシントンおよびｐｎａオリゴマーに関連する、組成物および方法